Centre Asset Management LLC reduced its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 5.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 80,610 shares of the biopharmaceutical company’s stock after selling 4,670 shares during the period. Alexion Pharmaceuticals accounts for 2.0% of Centre Asset Management LLC’s holdings, making the stock its 19th biggest holding. Centre Asset Management LLC’s holdings in Alexion Pharmaceuticals were worth $8,718,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Alexion Pharmaceuticals by 1.3% in the second quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock valued at $2,180,703,000 after purchasing an additional 211,960 shares in the last quarter. BlackRock Inc. increased its stake in Alexion Pharmaceuticals by 1.2% in the second quarter. BlackRock Inc. now owns 16,225,615 shares of the biopharmaceutical company’s stock valued at $2,125,230,000 after purchasing an additional 199,298 shares in the last quarter. Nuveen Asset Management LLC increased its stake in Alexion Pharmaceuticals by 57,650.8% in the second quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock valued at $476,393,000 after purchasing an additional 3,630,846 shares in the last quarter. Bank of America Corp DE increased its stake in Alexion Pharmaceuticals by 0.7% in the second quarter. Bank of America Corp DE now owns 2,078,585 shares of the biopharmaceutical company’s stock valued at $272,253,000 after purchasing an additional 13,426 shares in the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in Alexion Pharmaceuticals by 6.9% in the second quarter. UBS Asset Management Americas Inc. now owns 1,564,135 shares of the biopharmaceutical company’s stock valued at $204,870,000 after purchasing an additional 100,509 shares in the last quarter. 91.53% of the stock is owned by hedge funds and other institutional investors.

Several research firms have weighed in on ALXN. ValuEngine raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. BidaskClub downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 7th. Oppenheimer decreased their price target on shares of Alexion Pharmaceuticals from $165.00 to $150.00 in a research note on Thursday, October 24th. Evercore ISI reaffirmed a “buy” rating and issued a $145.00 price target on shares of Alexion Pharmaceuticals in a research note on Sunday, November 17th. Finally, William Blair reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $154.16.

Shares of NASDAQ:ALXN traded down $1.13 during midday trading on Tuesday, hitting $112.79. 2,283,198 shares of the company’s stock were exchanged, compared to its average volume of 1,852,141. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.45. The stock has a 50 day moving average price of $110.54 and a 200-day moving average price of $110.36. The company has a market cap of $24.23 billion, a PE ratio of 15.91, a price-to-earnings-growth ratio of 0.77 and a beta of 1.64. Alexion Pharmaceuticals, Inc. has a 12 month low of $94.59 and a 12 month high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, topping the consensus estimate of $2.47 by $0.32. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.24 billion. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The firm’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.02 earnings per share. On average, analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.44 EPS for the current fiscal year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: How prevalent are 12b-1 fees?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.